Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 64.14% | 102.56% | 118.64% | 40.23% | 10.91% |
| Total Depreciation and Amortization | 181.48% | 65.96% | 4.56% | 11.07% | 15.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.78% | 0.48% | -7.51% | 63.61% | 43.45% |
| Change in Net Operating Assets | 136.43% | -515.32% | -856.64% | -570.83% | 8.07% |
| Cash from Operations | 67.37% | 58.31% | 62.99% | 31.46% | 33.67% |
| Capital Expenditure | 40.27% | 28.24% | 14.06% | 10.99% | -20.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 784.37% | 7,331.31% | -3,998.49% | -160.05% | -5.40% |
| Cash from Investing | -152.18% | -1,426.03% | -1,262.50% | -108.52% | -7.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 67.48% | 130.76% | 43.42% | 5.98% | -30.78% |
| Repurchase of Common Stock | 51.96% | 73.40% | 71.69% | 44.10% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 83.48% | 115.64% | 99.04% | 92.13% | -126.66% |
| Foreign Exchange rate Adjustments | -- | -200.00% | -- | -- | -150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,468.54% | -46.18% | 135.81% | 2,751.93% | -116.06% |